However, results from the I-SPY 2 trial demonstrate that the pathologic complete response rate in patients with HER2+ breast cancer treated with MK-2206 and standard neoadjuvant is improved when compared to neoadjuvant therapy alone, predicting a high probability of success in phase III trial [213]. Here, ERBB2 is linked to breast carcinoma.